A new world of pain management

Regeneus is an Australian biotechnology company aiming to improve the quality of life of the hundreds of millions of patients worldwide suffering from long and short term pain.

Pain and inflammation are responsible for a series of events leading to immune cells reacting to damaged tissue, causing chronic and acute illness.

The Company develops regenerative medicine products that interrupt the inflammatory cascade that leads to pain, including its two leading stem cell technologies, Progenza™ – which has been licenced to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus – which is in pre-clinical stage.

At Regeneus we pride ourselves in our ability to create research collaborations and further our knowledge to advance our therapies.

By creating scientific communities we have been able to advance our methods and quality selection criteria to obtain highly scalable and highly potent products.

Through scientific co-creation we are advancing the field of pain therapy and providing relief to millions of people around the world.

Our history

Regeneus was founded in 2007 and listed on the Australian Securities Exchange (ASX) in September 2013. In 2019, Regeneus consolidated the company's strategic direction to target the global pain market with an initial focus on its lead platform technology, Progenza™.

A Pioneer in Cell therapy treatment Regeneus began our mission in autologous cell therapy for patients suffering from arthritis, we utilized our experience and knowledge to shift to innovative allogeneic cell therapy for broader application, democratizing MSCs for the treatment of pain for millions of everyday people.


Regeneus listed on the ASX under ticker code 'RGS'


First patient in Progenza™ STEP trial treated for Knee Osteoarthritis


Progenza™ meets safety endpoints and efficacy in STEP trial for patients with Knee Osteoarthritis

Sygenus shows more potent and longer lasting effect on pain than morphine in preclinical study


Positive preclinical trial results for Progenza™ in treating neuropathic pain


Regeneus signs licence and collaboration agreement with Kyocera Corporation for the commercialisation of Progenza™ for the treatment of knee osteoarthritis in Japan

A bold new vision

Mesenchymal Signalling Cells (MSC) and Secretome

Regeneus’ technology is based on Mesenchymal Signalling Cells (MSC) and their Secretome. To repair tissue and decrease inflammation, MSCs communicate via signalling molecules produced by the cells themselves, restoring the balance and calming the inflammatory state. These bioactive communications or signalling molecules are collectively termed ‘Secretome’. Regeneus uses both MSCs and Secretome to target pain and inflammation. Regeneus has two technology platforms, Progenza™ and Sygenus.

Research and Development Partners

In August 2020, Regeneus signed an exclusive licence and collaboration agreement with Kyocera Corporation to commercialisation Regeneus' lead stem cell technology platform Progenza™ to treat knee osteoarthritis in Japan.

Regeneus collaborated with A/Professor Tracy Heng of Monash University on a project researching the Mechanism of Action of MSC and immunomodulation.

Professor Tracy Heng is a Laboratory Head in the Department of Anatomy and Developmental Biology, Faculty of Medicine, Nursing and Health Sciences at Monash University.

Regeneus worked with Professor Mark Hutchinson of the University of Adelaide on a project researching the Mechanism of action of MSC and neuropathic pain.

Professor Mark Hutchinson is a Professor within the Adelaide Medical School and is the Director of the ARC Centre of Excellence for Nanoscale BioPhotonics.

In a partnership with UNSW, Regeneus worked with Professor Ewa Goldys on research for the Mechanism of action of MSC and neuropathic pain.

Professor Ewa Goldys is Deputy Director of the flagship interdisciplinary ARC Centre of Excellence for Nanoscale Biophotonics.

In a partnership with UTS, Regeneus worked with Dr Majid E Warkiani on research relating to the Microfluidic characterisation and isolation of MSC secretions.

Dr Majid E Warkiani is an Associate Professor in the School of Biomedical Engineering at UTS, Sydney, Australia.

Regeneus has been working with the Agency for Science, Technology and Research (A*STAR) in Singapore to conduct research for upscale manufacturing of MSC and MSC secretions.

On this project, Regeneus collaborated with Dr Steve Oh who is the Director Stem Cell Bioprocessing & Institute Professor, at A*Star, Singapore.

Research & Scientific Publications

A selected list of scientific publications related to Regeneus, Mesenchymal Signalling Cells (MSC) and their Secretome.

Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al
TISSUE ENGINEERING. Mary Ann Liebert, Inc; 2001.

Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, et al
Exp Hematol. 2005;33: 1402–1416. doi:10.1016/j.exphem.2005.07.003

Ankrum JA, Ong JF, Karp JM
Nat Biotechnol. 2014;32: 252–260. doi:10.1038/nbt.2816

Blazquez R, Sanchez-Margallo FM, de la Rosa O, Dalemans W, lvarez V, Tarazona R, et al
Front Immunol. 2014; doi:10.3389/fimmu.2014.00556

Mazor M, Lespessailles E, Coursier R, Daniellou R, Best TM, Toumi H
J Cell Mol Med. Wiley-Blackwell; 2014;18: 2340–50. doi:10.1111/jcmm.12378